Effects of nutrient in Japanese subjects with knee pain: a randomized, double-blind, placebo-controlled, parallel pilot study.

Effects of nutrient in Japanese subjects with knee pain: a randomized, double-blind, placebo-controlled, parallel pilot study. - Effects of nutrient in Japanese subjects with knee pain

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031558

Enrollment

Registered

2018-03-02

Start date

2011-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee pain

Interventions

Active supplement (continuous intake for 12W) Placebo supplement (continuous intake for 12W)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Subjects who have high scores of JKOM(II-V)

Exclusion criteria

Exclusion criteria: -Subjects who have therapeutic history for at least 2 year for knee joint pain -Subjects who suffer from articular rheumatism -Subjects who suffer from liver or kidney disease -Subjects who have therapeutic history for serious liver, kidney or heart disease -Subjects who have medication for knee joint pain (anodyne, anti-inflammation) -Subjects who have therapeutic history for at least 1 year for serious locomotor system (for example, a fracture, a tendon rapture, a pulled muscle) -Subjects who take excess alcohol -Subjects who take supplement including chondroitin sulfate or glucosamine for knee joint pain in daily -Subjects who are not eligible due to physician's judgment

Design outcomes

Primary

Measure	Time frame
VAS score of knee pain, JKOM score	—

Secondary

Measure	Time frame
Blood metabolite concentrations, Blood enzyme activities	—

Countries

Japan

Contacts

Public ContactShingo Kakuo

Kao Corporation Biological Science Laboratory

kakuo.shingo@kao.com+81-285-68-7440

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026